Many of the trials targeting inflammatory pathways, such as TNF-α inhibitors, anti-IL-1 therapy, and IMT treatment, suggest that the myocardium is more amenable to anti-inflammatory therapy at earlier HF stages, while in advanced HF, treatment efficacy remains limited. This evidence concerns the gene TNF and hydrops fetalis.